{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:17Z","timestamp":1759401677444,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"crossref","award":["RF-2016-02361610"],"award-info":[{"award-number":["RF-2016-02361610"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PREPARE MoH; project 3398"],"award-info":[{"award-number":["PREPARE MoH; project 3398"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Spastic ataxia of Charlevoix-Saguenay is a neurodegenerative condition due to mutations in the <jats:italic>SACS<\/jats:italic> gene and without a cure. Attempts to treatments are scarce and limited to symptomatic drugs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>Two siblings harboring biallelic variants in <jats:italic>SACS<\/jats:italic> underwent oral supplementation (600\u2009mg\/die) with docosahexaenoic acid (DHA), a well-tolerated dietary supplement currently used in SCA38 patients. We assessed over a 20\u2009month-period clinical progression using disease-specific rating scales.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>DHA was safe over a long period and well-tolerated by the two patients; both showed a stabilization of clinical symptoms, rather than the expected deterioration, warranting additional investigations in patients with mutations in <jats:italic>SACS<\/jats:italic>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-020-01803-3","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T07:02:43Z","timestamp":1590649363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Docosahexaenoic acid in ARSACS: observations in two patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Ivana","family":"Ricca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo Maria","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-9062","authenticated-orcid":false,"given":"Filippo Maria","family":"Santorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"1803_CR1","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/mds.25604","volume":"28","author":"A Duquette","year":"2013","unstructured":"Duquette A, Brais B, Bouchard J-P, Mathieu J. Clinical presentation and early evolution of spastic ataxia of Charlevoix-Saguenay. Mov Disord. 2013;28:2011\u20134. https:\/\/doi.org\/10.1002\/mds.25604.","journal-title":"Mov Disord"},{"key":"1803_CR2","doi-asserted-by":"publisher","first-page":"11878","DOI":"10.1038\/s41598-019-48047-x","volume":"9","author":"F Morani","year":"2019","unstructured":"Morani F, Doccini S, Sirica R, Paterno M, Pezzini F, Ricca I, et al. Functional Transcriptome analysis in ARSACS KO cell model reveals a role of Sacsin in autophagy. Sci Rep. 2019;9:11878. https:\/\/doi.org\/10.1038\/s41598-019-48047-x.","journal-title":"Sci Rep"},{"key":"1803_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.plefa.2007.10.023","volume":"77","author":"SI Rapoport","year":"2007","unstructured":"Rapoport SI, Rao JS, Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fat Acids. 2007;77:251\u201361. https:\/\/doi.org\/10.1016\/j.plefa.2007.10.023.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"issue":"Supplement","key":"1803_CR4","doi-asserted-by":"publisher","first-page":"S400","DOI":"10.1194\/jlr.R800068-JLR200","volume":"50","author":"NG Bazan","year":"2009","unstructured":"Bazan NG. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer\u2019s disease. J Lipid Res. 2009;50(Supplement):S400\u20135. https:\/\/doi.org\/10.1194\/jlr.R800068-JLR200.","journal-title":"J Lipid Res"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.phrs.2018.07.004","volume":"135","author":"S Shirooie","year":"2018","unstructured":"Shirooie S, Nabavi SF, Dehpour AR, Belwal T, Habtemariam S, Arg\u00fcelles S, et al. Targeting mTORs by omega-3 fatty acids: a possible novel therapeutic strategy for neurodegeneration? Pharmacol Res. 2018;135:37\u201348. https:\/\/doi.org\/10.1016\/j.phrs.2018.07.004.","journal-title":"Pharmacol Res"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ana.25059","volume":"82","author":"M Manes","year":"2017","unstructured":"Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38. Ann Neurol. 2017;82:615\u201321. https:\/\/doi.org\/10.1002\/ana.25059.","journal-title":"Ann Neurol"},{"key":"1803_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.parkreldis.2019.02.040","volume":"63","author":"M Manes","year":"2019","unstructured":"Manes M, Alberici A, Di Gregorio E, Boccone L, Premi E, Mitro N, et al. Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: an open label extension study. Parkinsonism Relat Disord. 2019;63:191\u20134. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.040.","journal-title":"Parkinsonism Relat Disord"},{"key":"1803_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.phrs.2015.05.015","volume":"99","author":"R Abeti","year":"2015","unstructured":"Abeti R, Uzun E, Renganathan I, Honda T, Pook MA, Giunti P. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich\u2019s ataxia. Pharmacol Res. 2015;99:344\u201350. https:\/\/doi.org\/10.1016\/j.phrs.2015.05.015.","journal-title":"Pharmacol Res"},{"key":"1803_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10048-019-00564-7","volume":"20","author":"I Ricca","year":"2019","unstructured":"Ricca I, Morani F, Bacci GM, Nesti C, Caputo R, Tessa A, et al. Clinical and molecular studies in two new cases of ARSACS. Neurogenetics. 2019;20:45\u20139. https:\/\/doi.org\/10.1007\/s10048-019-00564-7.","journal-title":"Neurogenetics."},{"key":"1803_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1212\/01.wnl.0000228242.53336.90","volume":"67","author":"R Sch\u00fcle","year":"2006","unstructured":"Sch\u00fcle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, et al. The spastic paraplegia rating scale (SPRS): a reliable and valid measure of disease severity. Neurology. 2006;67:430\u20134. https:\/\/doi.org\/10.1212\/01.wnl.0000228242.53336.90.","journal-title":"Neurology."},{"key":"1803_CR11","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000219042.60538.92.","journal-title":"Neurology."},{"key":"1803_CR12","doi-asserted-by":"publisher","first-page":"e1543","DOI":"10.1212\/WNL.0000000000008313","volume":"93","author":"C Gagnon","year":"2019","unstructured":"Gagnon C, Brais B, Lessard I, Lavoie C, C\u00f4t\u00e9 I, Mathieu J. Development and validation of a disease severity index for ataxia of Charlevoix-Saguenay. Neurology. 2019;93:e1543\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000008313.","journal-title":"Neurology."},{"key":"1803_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2018.03.033","volume":"390","author":"I Lessard","year":"2018","unstructured":"Lessard I, Brais B, C\u00f4t\u00e9 I, Lavoie C, Synofzik M, Mathieu J, et al. Assessing mobility and balance in autosomal recessive spastic Ataxia of Charlevoix-Saguenay population: validity and reliability of four outcome measures. J Neurol Sci. 2018;390:4\u20139. https:\/\/doi.org\/10.1016\/j.jns.2018.03.033.","journal-title":"J Neurol Sci"},{"key":"1803_CR14","doi-asserted-by":"publisher","first-page":"e1307","DOI":"10.1212\/WNL.0000000000006290","volume":"91","author":"C Gagnon","year":"2018","unstructured":"Gagnon C, Lessard I, Lavoie C, C\u00f4t\u00e9 I, St-Gelais R, Mathieu J, et al. An exploratory natural history of ataxia of Charlevoix-Saguenay. Neurology. 2018;91:e1307\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000006290.","journal-title":"Neurology."},{"key":"1803_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13023-018-0898-z","volume":"13","author":"C Gagnon","year":"2018","unstructured":"Gagnon C, Brais B, Lessard I, Lavoie C, C\u00f4t\u00e9 I, Mathieu J. From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay. Orphanet J Rare Dis. 2018;13:165. https:\/\/doi.org\/10.1186\/s13023-018-0898-z.","journal-title":"Orphanet J Rare Dis"},{"key":"1803_CR16","first-page":"e 1 1 4 5 7\/1","volume":"12","author":"L Scalone","year":"2015","unstructured":"Scalone L, Cortesi PA, Ciampichini R, Mantovani G, Cesana GML. Health Related Quality of Life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Heal. 2015;12:e 1 1 4 5 7\/1\u2013e 1 1 4 5 7\/1 5.","journal-title":"Epidemiol Biostat Public Heal"},{"key":"1803_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fneur.2019.00003","volume":"10","author":"M Bellofatto","year":"2019","unstructured":"Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM. Management of Hereditary Spastic Paraplegia: a systematic review of the literature. Front Neurol. 2019;10:3. https:\/\/doi.org\/10.3389\/fneur.2019.00003.","journal-title":"Front Neurol"},{"issue":"1","key":"1803_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","volume":"6","author":"TA Jacobson","year":"2012","unstructured":"Jacobson TA, Glickstein SB, Rowe JDSP. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6(1):5\u201318.","journal-title":"J Clin Lipidol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01803-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01803-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:29:06Z","timestamp":1622161746000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01803-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01803-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Ethic Committee. Written consent was obtained from all study participants patients for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from study participants for publication of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}